In the morning of January 23, 2020, Professor Ming-Wei Wang, Director of the National Center for Drug Screening/Chinese National Compound Library and Dean of School of Pharmacy, Fudan University met with his old friend and a senior biopharmaceutical entrepreneur, Dr. Richard Keatinge, in San Diego (California, U.S.A.). They discussed clinical indications and development prospect of anti-cancer drug leads against PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3) and decided to conduct in-depth studies in this area.